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EXPERT OPINION
Abstract: Rufinamide, a triazole derivative that is structurally distinct from currently marketed
antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut
syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration,
demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without
involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a
randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared
with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop
attacks (median change –42.5% vs +1.4% with placebo) and total seizures (–32.1% vs –
11.7% with placebo), accompanied by significantly higher responder rates. These results are
comparable with findings reported for other AEDs in randomized, controlled clinical trials in
patients with LGS. Rufinamide produced statistically significant seizure reduction which
was maintained during long-term therapy and accompanied by good tolerability. The most
frequently reported adverse events from a pooled safety database evaluating short- and long-
term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue
(13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile
and is a promising candidate for the adjunctive therapy of LGS.
Keywords: antiepileptic drug, Lennox-Gastaut syndrome, pediatrics, rufinamide
Introduction
Rufinamide (1-[(2,6-difluorophenyl)methyl]-1hydro-1,2,3-triazole-4 carboxamide)
is a novel antiepileptic drug (AED) that is structurally distinct from other AEDs
available on the market (Levy et al 2002a). An application was filed by Eisai Ltd in
2005 for European approval of this agent as an adjunctive treatment for seizures
associated with Lennox-Gastaut Syndrome (LGS) in children and adults (Eisai Co
Ltd 2005).
Lennox-Gastaut syndrome is a catastrophic epileptic encephalopathy of childhood
onset (typically at age 3–5 years), for which effective treatment options are limited.
This syndrome is associated with multiple types of generalized seizures, especially
drop attacks and tonic seizures, delayed psychomotor development, behavioral and
personality disorders, and a characteristic electroencephalogram pattern containing
both generalized slow spike wave activity and paroxysms of generalized fast rhythmic
activity during sleep which reflect excessive neocortical excitability (Markand 2003;
Nabbout and Dulac 2003; Guerrini 2006). The long-term prognosis is very poor,
with persistence of seizures in more than 75% of patients and severe mental retardation
in more than 50% of patients (Markand 2003; Dulac and Engel 2003; Schmidt and
Bourgeois 2000). Patient quality of life is particularly affected by the drop attacks.
Consequently, LGS is viewed as one of the most difficult epilepsies to treat.
Currently available treatment options for the epileptic encephalopathies in Europe
center around the use of valproate, with adjunctive benzodiazepines, topiramate,
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lamotrigine, or felbamate (Guerrini 2006). However, a
Cochrane review has concluded that no single AED could
be considered highly efficacious for LGS (Hancock and
Cross 2003). Indeed, the efficacy of valproate as a first-line
treatment has been described as “unimpressive”, and its use
in young children should be accompanied by great caution
due to the risk of life-threatening hepatic toxicity (Schmidt
and Bourgeois 2000). Other first-generation AEDs
(carbamazepine, phenytoin, and phenobarbital) are not
recommended for the treatment of LGS, due to the potential
for aggravation of absence and myoclonic seizures by
carbamazepine and phenytoin, and exacerbation of the
behavioral problems seen in patients with LGS by
barbiturates. Among the benzodiazepines, clobazam may
be viewed as the best tolerated, although there is no head-
to-head comparison to confirm this. However, for this class
of drugs, development of tolerance is well documented in
the literature (Levy et al 2002b). The only AEDs which have
been evaluated in a randomized, controlled trial in LGS are
lamotrigine, topiramate, and felbamate, the outcomes of
which are discussed later in this paper. Although felbamate
is licenced for the treatment of LGS in the USA and some
other countries (eg, Germany), its use has been limited
following reports of serious toxicity (Borowicz et al 2004).
This has led to the recommendation that, in LGS, it should
be used only in patients aged over 4 years who cannot be
treated satisfactorily with other AEDs (Schmidt and
Bourgeois 2000).
Thus, there is a clear need for new options in the
management of this intractable condition. Rufinamide was
granted orphan drug status by the European Medicines
Agency (EMEA) and the US Food and Drug Administration
(FDA) in 2005. This review will evaluate the relevant
pharmacologic and clinical data for rufinamide, and explore
its potential role in the future management of this severe
form of epilepsy in the context of other products currently
available for LGS.
Pharmacology and
pharmacokinetics of rufinamide
An extensive preclinical evaluation has suggested that the
principal mechanism involved in the antiepileptic activity
of rufinamide is its ability to modulate the activity of sodium
channels, limiting high-frequency firing of neuronal action
potentials over a broad range of concentrations, as
demonstrated in vitro (McLean et al 2005). In radioligand
binding studies, rufinamide does not interact with other
neurotransmitter systems, including monoamine, adenosine,
acetylcholine, histamine, glycine, α-amino-3-hydroxy-5-
methyl-4-isoxazole propionate (AMPA)/kainite, N-methyl-
D-aspartate (NMDA), and γ-amino butyric acid (GABA)
systems (Bialer et al 1996).
Rufinamide has demonstrated broad spectrum
anticonvulsant activity in animal models of epilepsy,
elevating both electrically and chemically induced seizure
thresholds and preventing seizure spread following oral and
intraperitoneal administration in mice and rats (White et al
2005). No tolerance to this activity was observed following
chronic administration over 5 days. Furthermore, the
protective index for rufinamide (ratio of the concentration
required for 50% anticonvulsant efficacy to that for
neurotoxicity) was superior to that of each of the comparator
AEDs examined (phenytoin, phenobarbital, ethosuximide,
and valproate).
The pharmacokinetic properties of rufinamide have been
established both in healthy volunteers and in patients with
epilepsy. In a study of 3 healthy volunteers, an oral dose of
600 mg rufinamide demonstrated high absorption, and
monoexponential elimination with a mean half-life (t½) of
9 hours (Waldmeier et al 1996). Excretion was largely renal
(85%) and complete (98%) within 7 days. Following
administration of 400 mg rufinamide as two 200-mg tablets
or 400-mg oral suspension after a standard meal, mean
maximum plasma concentrations (Cmax) of 3.03 and 3.32 μg/
mL were reached after 6.6 and 7.2 hours, respectively,
leading to elimination with a terminal t½ of 8.8 and 9.1 hours,
respectively (Cheung et al 1995). In a further study, the
absorption of a single dose of 400 mg rufinamide was
accelerated in fed subjects compared with fasting conditions,
resulting in a 43% increase in exposure (96-hour exposure),
without affecting the t½ (Cardot et al 1998). However, no
effect of food was observed with repeat dosing (Eisai, data
on file), and no difference in rufinamide pharmacokinetics
has been found between older (aged 66–77 years) and
younger (18–40 years) healthy subjects in either single- or
multiple-dosing conditions (Chang et al 1998). Rufinamide
pharmacokinetics in a study of 16 children aged between 2
and 17 years treated with 10 or 30 mg/kg daily rufinamide
for 2 weeks were also comparable to those reported
elsewhere for adult patients (Sachdeo et al 1998). Overall,
evaluation of these data suggests that no age-related dose
adjustments are likely to be required for either pediatric or
elderly populations (Bialer et al 2001).
The pharmacokinetic parameters of single ascending
doses of rufinamide (0, 400, 800, 1200 mg) have also been
compared between 3 healthy subjects and 16 patients withNeuropsychiatric Disease and Treatment 2007:3(1) 5
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epilepsy receiving enzyme-inducing AEDs (Brunner et al
1994). Absorption rates were comparable, and both groups
showed dose-related increases in Cmax and exposure.
Rufinamide elimination was accelerated in AED-treated
patients compared with healthy subjects, but t½ was
independent of the dose administered in both groups. The
pharmacokinetics of rufinamide have also been evaluated
in 129 pediatric and adult patients with LGS (Critchley et
al 2005). Rufinamide clearance was not affected by
concomitant lamotrigine or topiramate, and was also
unaffected by liver or kidney function. However, rufinamide
concentrations were increased by concomitant valproate:
40% in children and 11% in adults. Therefore, the rufinamide
dosage may require adjustment during the addition or
withdrawal of concomitant valproate therapy.
Rufinimade is extensively metabolized (2% excreted
unchanged in urine and 2% in feces), predominantly via
hydrolysis of the carboxylamide group to yield an inactive
metabolite (CGP-27292), and is largely excreted in urine
(84.7% of dose) (Bialer et al 1999). Thus, rufinamide has a
low propensity for drug–drug interactions, based on its low
protein binding (approximately 34%) and absence of
metabolism via hepatic cytochrome P450 or inhibition of
the major enzyme subclasses (Bialer et al 1996; Kapeghian
et al 1996). This is supported by the absence of clinically
relevant alterations of concomitant AED levels observed in
a population pharmacokinetic drug–drug interaction analysis
(Fuseau et al 2005). This analysis was conducted using data
from 5 double-blind studies involving pediatric and adult
patients with inadequately controlled seizures despite
previous treatment with up to 3 AEDs. In total, 903 patients
were receiving carbamazepine, 588 valproate, 200
lamotrigine, 299 phenytoin, 149 phenobarbital, and 69
topiramate. Rufinamide co-administration did not affect the
clearance of topiramate or valproate, but increased the
clearance of carbamazepine and lamotrigine and decreased
clearance of phenobarbital and phenytoin. However, all
produced effects were small, were considered unlikely to
be  of  clinical  significance,  and  were  independent  of
age. At a rufinamide plasma concentration of 15 μg/mL,
representing steady-state concentrations following doses of
45 mg/kg daily in children or 3200 mg/day in adults, changes
in clearance were under 18% of the values without
rufinamide (Fuseau et al 2005). Conversely, in a similar
study involving 471 patients, valproate co-administration
decreased rufinamide clearance by approximately 22%,
while any combination of phenytoin, phenobarbital, or
primidone increased rufinamide clearance by approximately
25%, compared with patients not receiving these AEDs
(Bialer et al 2001). Rufinamide also resulted in a small
increase in clearance of the oral contraceptive Ortho-
Novum
® (Ortho-Mcneil Pharmaceutical, Inc. Raritan, NJ,
USA) 1/35 in healthy female volunteers, though the clinical
relevance of this effect is not known (Svendsen et al 1998).
Rufinamide in Lennox-Gastaut
syndrome
The efficacy of rufinamide as an adjunctive therapy for
treatment-resistant LGS has been evaluated in a multicenter,
randomized, 12-week, double-blind, placebo-controlled,
parallel-group study in 138 patients aged 4–37 years (mean
age 14.1 years), followed by an open-label extension phase
(Glauser et al 2005a, 2005b). Patients diagnosed with LGS,
experiencing ≥90 seizures in the month prior to study entry,
and receiving stable treatment with 1–3 concomitant AEDs,
were evaluated. After a 28-day baseline, patients randomized
to twice-daily oral treatment with rufinamide (n=74) or
placebo (n=64) entered a 14-day titration period (rufinamide
target dose 45 mg/kg daily), followed by 70 days of double-
blind maintenance treatment. The reduction from baseline
in the frequency of tonic-atonic seizures (drop attacks) per
28 days was significantly greater with rufinamide than
placebo (median change –42.5% vs +1.4%, respectively,
p<0.0001). Similarly, the reduction from baseline in total
seizure frequency per 28 days was significantly greater with
rufinamide than placebo treatment (median change –32.7%
vs –11.7%, respectively, p=0.0015). These improvements
were associated with significantly greater proportions of
responders (patients achieving ≥50% reduction in seizures
per 28 days) with rufinamide than placebo treatment, both
for tonic-atonic seizures (42.5% vs 16.7%, p=0.0020)
(Glauser et al 2005a) and total seizure frequency (31.1% vs
10.9%, p=0.0045) (Kluger et al 2006).
Following completion of the double-blind study, 123
patients continued to receive open-label treatment in the
extension phase, at a median dose of 1800 mg/day (range
103–4865 mg/day) for a median duration of 432 days (range
10–1149 days) (Glauser et al 2005b). The reduction in
median total seizure frequency observed at 12 weeks was
maintained, with some further improvement noted with
continued treatment for up to 3 years (see Figure 1).
Similarly, the responder rate for total seizures was
maintained, with 36.9% of patients achieving a reduction
in total seizures of at least 50% overall during the extension
study. Furthermore, 21.3% of patients achieved a ≥75%Neuropsychiatric Disease and Treatment 2007:3(1) 6
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reduction in total seizures overall during the extension study.
There was no evidence for tolerance to rufinamide treatment.
Tolerability and safety of
rufinamide
During the double-blind study of rufinamide in patients with
LGS, the most common adverse events (reported by ≥10%
patients in either treatment group) were: somnolence (24.3%
rufinamide, 12.5% placebo), vomiting (21.6% rufinamide,
6.3% placebo), pyrexia (13.5% rufinamide, 17.2% placebo),
and diarrhea (5.4% rufinamide, 10.9% placebo) (Glauser et
al 2005a). Notably, rufinamide treatment was associated
with a lower incidence of cognitive/psychiatric adverse
events (such as psychomotor hyperactivity and lethargy)
than placebo treatment (17.6% vs 23.4%, respectively).
There was no clinically significant change in clinical
laboratory tests, physical examinations or vital signs. During
the subsequent open-label extension study, the most
commonly reported all-causality adverse events were
vomiting (30.6%), pyrexia (25.8%), upper respiratory tract
infection (21.8%), and somnolence (21.0%) (Glauser et al
2005b). There were two deaths, which were not considered
to be related to rufinamide treatment. Thus, long-term
treatment of patients with LGS does not appear to be
associated with any increase in central nervous system
(CNS) adverse events, with somnolence noted with
somewhat lower frequency than during the double-blind
phase.
These tolerability and safety data in patients with LGS
are further supported by a pooled analysis of rufinamide
tolerability and safety in a large population of epilepsy
patients, in which the data were evaluated separately for
patients receiving short-term or long-term treatment (Krauss
et al 2005). The short-term safety population comprised
1240 patients treated with rufinamide (mean age 31.7 years;
mean rufinamide dose 1373 mg/day; mean duration of
treatment 2.8 months) and 635 placebo recipients (mean
age 28.6 years, mean duration of treatment 3.0 months).
Somnolence was reported somewhat less frequently in this
population than in the LGS study, with an incidence of
11.8% for rufinamide and 9.1% among placebo recipients.
The timing of events in this pooled analysis indicated a
pattern of early onset and rapid resolution, and a tolerability
profile not substantially different from placebo; the
incidence of the most frequently reported adverse events
with rufinamide vs placebo were headache (22.9% vs
18.9%), dizziness (15.5% vs 9.4%), fatigue (13.6% vs
9.0%), somnolence (11.8% vs 9.1%), and nausea (11.4%
vs 7.6%).
This favorable tolerability and safety profile was
maintained with long-term administration. The pooled
tolerability and safety analysis included 1978 patients
assessed for long-term tolerability and safety (mean age 31.3
years, mean rufinamide dose 1700 mg/day, maximum dose
7200 mg/day), 47% of whom were treated with rufinamide
for at least 12 months; the most frequently reported adverse
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Figure 1 Median percentage reduction from baseline in total seizure frequency during 12-week double-blind and subsequent open-label rufinamide treatment
(Glauser 2005a, 2005b; Eisai, data on file). Data shown separately for patients receiving rufinamide (n=74) or placebo (n=64) during double-blind treatment (Glauser
2005a), and combined for patients continuing in the extension study and receiving open-label rufinamide treatment (n=124) (Glauser 2005b).Neuropsychiatric Disease and Treatment 2007:3(1) 7
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events in this population were headache (29.5%), dizziness
(22.5%), and fatigue (17.7%) (Krauss et al 2005).
Rufinamide in context
Other randomized controlled trials in
LGS
Few randomized, controlled clinical trials have been
conducted in patients with LGS, none of which is a head-
to-head comparison. Consequently, the available treatments
for LGS cannot be compared directly, and only limited
conclusions may be drawn from indirect comparisons.
The most robust approaches for indirect comparisons
include systematic reviews and meta-analyses, such as those
conducted by the Cochrane Group. A systematic (Cochrane)
review of randomized, controlled trials in LGS (Hancock
and Cross 2003) retrieved only 5 evaluable studies: one each
conducted with topiramate, lamotrigine, felbamate,
cinromide, and a thyrotropin releasing hormone (TRH)
derivative, respectively (Anonymous 1989, 1993; Inanaga
et al 1989; Motte et al 1997; Sachdeo et al 1999). This review
concluded that no single agent was found to be highly
efficacious in LGS, and that of those evaluated only
lamotrigine, topiramate and felbamate were considered
potentially efficacious as add-on therapy (Hancock and
Cross 2003).
Data derived from this Cochrane analysis for each of
the clinical trials are summarized in Table 1, together with
data from the more recently reported rufinamide study
(Glauser et al 2005a). Although this provides an indirect
comparison, it is of interest to note that rufinamide produced
a particularly marked effect in the reduction in drop attacks
(tonic-atonic seizures), since this is also the parameter
viewed as the primary outcome variable for LGS according
to guidelines from the American Academy of Neurology
(French et al 2004). The median reduction in tonic-atonic
seizures was 42.5% with rufinamide, which compares well
with rates observed in the separate studies with topiramate
(14.8% reduction) or lamotrigine (34% reduction); the effect
of felbamate on drop attacks was not reported. When
corrected for the magnitude of placebo response, the median
effect size for rufinamide on drop attacks was 41.1%,
compared with 19.9% for topiramate and 14.8% for
lamotrigine. Similarly, the proportion of patients who could
be considered responders to therapy (achieving at least a
50% decrease in drop attacks) was 42.5% with rufinamide,
45.6% with topiramate, and 37.3% with lamotrigine, or
25.8%, 25.6%, and 14.8%, respectively, when corrected for
placebo response.
As with drop attacks, the effects of these agents on total
seizure frequency produced some interesting findings. The
rufinamide, topiramate, and lamotrigine studies
demonstrated 32.7%, 20.6%, and 32.0% median reductions
in total seizures, and treatment effect sizes (adjusted for
placebo) of 20.0%, 12.6%, and 17.6%, respectively. In the
felbamate study, outcomes were reported as mean rather
than median values, resulting in a 19% mean reduction in
total seizures, and a 23% mean effect size. The number of
patients achieving complete cessation of seizures has only
been reported with felbamate, and although these results
are favorable, cannot be compared with the other AEDs in
the studies available to date.
Of course, the overall benefit of treatment comprises a
balance between reduction in (or cessation of) seizures and
tolerability/safety. The reported tolerability of treatment was
broadly comparable among the studies described in Table
1, with relatively small differences in rates of
discontinuations due to adverse events.
Additional tolerability and safety
considerations
Each of these currently available agents has been associated
with warnings relating to severe adverse events. The use of
felbamate has been restricted in many countries following
reports of idiosyncratic aplastic anemia and hepatic failure,
which led to its initial withdrawal in the USA, although
limited use was granted subsequently (FDA 1994). Similarly,
the efficacy of lamotrigine must be balanced against the
risk of serious skin reactions in susceptible individuals, for
which boxed warnings or safety alerts have been issued
(Committee on Safety of Medicines 1996; FDA 1997), while
the use of topiramate is associated with warnings relating
to oligohydrosis and hyperthermia in children, and also
metabolic acidosis and glaucoma (FDA 2003; Janssen-Cilag
2006). In addition, factors such as cognitive slowing and
weight loss may be issues with the use of topiramate (Levy
et al 2002c).
The timing of these warnings, some time after the initial
marketing of these AEDs, illustrates the difficulties in
identifying such events during clinical trials, and that further
evaluation is required to confirm the long-term safety of
rufinamide in comparison with the marketed drugs.
An additional consideration in the long-term use of
AEDs is cardiac safety. Indeed, increased QT interval
dispersion has been demonstrated in children with epilepsy,Neuropsychiatric Disease and Treatment 2007:3(1) 8
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Table 1 Overview of randomized, double-blind, controlled trials of adjunctive drug treatment for Lennox-Gastaut syndrome: data
from evaluable studies in Cochrane reviewa (Hancock and Cross 2003) and a recent double-blind trial of rufinamide (Glauser et al
2005a, Kluger et al 2006)
Study Patients and inclusion Treatments and Key outcomesb
reference criteria duration
Glauser et al n=138 (74 rufinamide, 28-day baseline Oucomes for rufinamide vs placebo:
 2005a 64 placebo) 14-day titration (placebo or  Median reduction in tonic-atonic seizure
Age 4–37 years (mean 14.1) rufinamide 45 mg/kg daily in frequency from baseline: 42.5% vs 1.4% (p<0.0001)
³90 seizures/month prior to 2 divided doses) Responder ratec for tonic-atonic seizures: 42.5%
baseline 70 days of maintenance vs 16.7% (p=0.0020)
Taking 1–3 AEDs at fixed doses treatment (median dose Median reduction in total seizure frequency: 32.7%
1800 mg/day) vs 11.7% (p=0.0015)
Patients with improvement in seizure frequency:
53.4% vs 30.6% (p=0.0041)
Discontinuations due to adverse events: 6 (3
vomiting, 2 somnolence, 2 rash) vs 0
No deaths reported
Sachdeo et al n=112 (48 topiramate, 50 4-week baseline Outcomes for topiramate vs placebo:
1999 placebo) 11 weeks of placebo or Median change in drop attacks: 14.8% reduction
Age 1–30 years topiramate (titrated over vs 5.1% increase (p=0.041)
Slow spike and wave on EEG; 3 weeks up to 6 mg/kg daily or Patients achieving complete cessation of drop
³60 seizures/month prior to maximal tolerated dose) attacks: 2.2% vs 0 (RR 3.3, CI 0.1–7.8)
baseline (including drop attacks Responder rate
c for drop attacks: 45.6% vs 20.0%
and atypical absence seizures)  (RR=2.9, CI 0.8–10.2 for ³75% reduction; RR=2.0,
Taking 1 or 2 AEDs     CI 0.9–4.6 for 50–74% reduction)
Median reduction in total seizures 20.6% vs 8.8%
(p=0.037)
No reported discontinuations due to adverse effects
or deaths
Motte et al n=179 (79 lamotrigine, 90 4-week baseline  Outcomes for lamotrigine vs placebo:
1997 placebo) 16 weeks of placebo or Median reduction in drop attacks: 34% vs 9%
Age 3–25 years lamotrigine (dose depending Responder rate
c for drop attacks: 37.3% vs 22.5%
>1 type of predominantly on concomitant valproate usage (p=0.04, RR=1.7, CI=1.0–2.7)
generalized seizure for ³1 year; and body weight) Responder ratec for tonic-clonic seizures: 43.3% vs
<11 years old at onset; 20.3% (RR=2.1, CI=1.2–3.8)
³1 seizure every 2 days; Responder rate
c for total seizures: 33.3% vs 15.7%
intellectual impairment and EEG (RR=2.1, CI=1.2–3.8)
with slow-wave complexes Median change in total seizure frequency: 32%
reduction vs 9% increase
Discontinuations: 3 (1 worsening seizures; 2 rash) vs
7 (6 worsening seizures; 1 rash)
No deaths reported
Anonymous n=73 (37 felbamate, 36 placebo) 28-day baseline Outcomes for felbamate vs placebo:
1993 ³90 atonic or atypical absence 14-day titration (placebo or Patients achieving complete cessation of seizures:
seizures/month during 8 weeks felbamate 15 mg/kg daily 10.8% vs 2.7% (p=0.2, RR=3.9, CI=0.5–33.2)
prior to baseline increasing to 30 mg/kg at Patients achieving complete cessation of atonic
Taking £2 AEDs 7  days  and the lower of either seizures: 17.9% vs 0% (p=0.1, RR=5.7,
14 mg/kg daily or 3600 mg/day CI=0.5–149.8)
at 14 days)  Patients achieving complete cessation of tonic-clonic
56 days of maintenance seizures: 43.7% vs 7.7% (p=0.08, RR=5.7,
treatment CI=0.8–40.5)
Mean change in total seizure frequency: 19%
reduction vs 4% increase (p=0.002)
Discontinuations: 1 (somnolence and ataxia) vs 1
(pancreatitis)
No deaths reported
aEvaluable studies as identified in a Cochrane review (Hancock and Cross 2003), plus recently reported randomized, double-blind trial of rufinamide (Glauser et al
2005a). bKey outcomes as reported by Glauser et al (2005a) for rufinamide study, and derived from data reported in Cochrane review (Hancock and Cross 2003) for
all other studies. cResponder rate defined as % patients achieving ³50% reduction from baseline in seizure frequency.
Abbreviations: AED, antiepileptic drug; CI, 95% confidence interval; EEG, electroencephalogram; RR, relative risk; TRH, thyrotropin releasing hormone.Neuropsychiatric Disease and Treatment 2007:3(1) 9
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potentially predisposing them to serious cardiac events
(Akalin et al 2003). Rufinamide has demonstrated excellent
cardiovascular tolerability, with no increase in QT intervals
in a cardiac safety study conducted in 15 healthy volunteers
treated with placebo or ascending doses of rufinamide (from
800 to 7200 mg/day) over 18 days (Marchand et al 2005).
On the contrary, rufinamide produced a small dose-
dependent decrease in QT.
Conclusions
LGS is a catastrophic and debilitating age-specific epileptic
disorder, for which a substantial unmet need exists for highly
effective treatment options. The data reviewed here indicate
that adjunctive therapy with rufinamide, a new AED that is
structurally unrelated to other currently available AEDs,
significantly reduces seizure frequency in patients with LGS,
accompanied by good tolerability, both of which are
maintained during long-term use. In particular, the reduction
in drop attacks adds substantially to patient quality of life.
The efficacy of rufinamide is most likely derived from
its ability to block sodium channels, thereby limiting high-
frequency action potential firing, a mechanism shared by
some other AEDs including phenytoin, carbamazepine,
lamotrigine, and oxcarbazepine (McLean et al 2005).
However, it is commonplace for patients with LGS to remain
symptomatic despite optimal therapy, and it is notable that,
in the studies reviewed, adjunctive rufinamide treatment was
able to exert significant improvement in a treatment-resistant
population receiving 1–3 other AEDs at baseline.
In an indirect comparison with randomized controlled
trials examining other AEDs, the results with rufinamide
appear impressive: a median reduction in drop attacks of
42.5% with rufinamide, compared with 14.8% with
topiramate and 34% for lamotrigine, representing treatment
effect sizes, after adjustment for placebo response, of 41.1%,
19.9%, and 14.8%, respectively. This was associated with a
median reduction in total seizures of 32.7% with rufinamide,
compared with 20.6% in the topiramate study and 32% in
the lamotrigine study. Although the full safety data for the
rufinamide study in LGS have yet to be reported, data from
a pooled safety database suggest a good tolerability profile
for both short- and long-term use of rufinamide, with a
pattern of early onset and early resolution of events.
Furthermore, this tolerability profile is accompanied by a
“clean” cardiac safety profile, based on a dose-ranging study
in healthy volunteers which included QT analysis. However,
Table 1 Continued
Study Patients and inclusion Treatments and Key outcomesb
reference criteria duration
Anonymous n=73 (26 cinromide, 30 placebo) 6-week baseline Outcomes for cinromide vs placebo:
1989 Age 2–18 years 18 weeks of placebo or Responder ratec for total seizures: 26.9% vs
³40 seizures/2 weeks during cinromide (20–40 mg/kg daily 23.3%
baseline; predominantly generalized in 4 divided doses, titrated up Patients achieving complete cessation of seizures: 0
slow spike and wave discharges on to 83–109 mg/kg as required) vs  0
EEG No significant benefit in any Cochrane analyses of
Taking ³3 marketed AEDs RR
No reported discontinuations due to adverse
events, or deaths
Inanaga et al n=98 with LGS (48 low dose 8 weeks of treatment with low Outcomes for high dose vs low dose:
1989 TRH, 50 high dose TRH) or high dose TRH DN-1417 Responder rate
c for absence seizures: 19.2% vs
Age >2 years or weight >15kg (0.4 mg/kg daily or 4.8%
Stable condition  1.6 mg/kg daily) Responder rate
c for tonic seizures: 20.8% vs
No excess AED-induced sedation  12.1%
Responder ratec for atonic seizures: 21.7% vs
20.0%
No significant RR of treatment effect with high-dose
 TRH; significant RR with low-dose TRH only for
achievement of 0–24% reduction in tonic seizures
(RR=2.0, CI=0.1–46.1)
No reported discontinuations due to adverse events,
or deaths
aEvaluable studies as identified in a Cochrane review (Hancock and Cross 2003), plus recently reported randomized, double-blind trial of rufinamide (Glauser et al
2005a). 
bKey outcomes as reported by Glauser et al (2005a) for rufinamide study, and derived from data reported in Cochrane review (Hancock and Cross 2003) for
all other studies. 
cResponder rate defined as % patients achieving ³50% reduction from baseline in seizure frequency.
Abbreviations: AED, antiepileptic drug; CI, 95% confidence interval; EEG, electroencephalogram; RR, relative risk; TRH, thyrotropin releasing hormone.Neuropsychiatric Disease and Treatment 2007:3(1) 10
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the full spectrum of efficacy as well as the safety profile of
rufinamide will become clear with accumulation of long-
term clinical experience and usage.
Overall, these findings suggest that rufinamide may be
a valuable option for the adjunctive treatment of LGS.
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